AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03256825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Real-time antimicrobial stewardship decision support
Description: A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~1. Switch to active treatment if non-working empirical treatment~2. De-escalate broad spectrum empiric treatment when feasible~3. Promote early intravenous to per oral switch~4. Shorten treatment duration
Study NCT02716948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02716948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02716948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT03968757 — intervention group
Intervention type: DEVICE
Intervention: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Description: Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
Study NCT02833688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
Study NCT02833688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
Study NCT02233933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemospray
Description: hemospray is used after argon coagulation to stop bleeding
Study NCT02233933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemospray
Description: hemospray is used after argon coagulation to stop bleeding
Study NCT04242433 — intervention group
Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent.
Study NCT03652974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate with Clozapine
Description: sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study NCT03652974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified electroconvulsive therapy(MECT) with Clozapine
Description: modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study NCT03652974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride with Clozapine
Description: amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study NCT03652974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo with Clozapine
Description: placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study NCT01638247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 25 mg daily.
Study NCT01638247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen and GnRH analogue
Description: 25 mg Tamoxifen daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months).
Study NCT01638247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane and GnRH analogue
Description: 25 mg Exemestane daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months).
Study NCT02170025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
Study NCT02170025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received matching placebo tid.
Study NCT03637244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Aid and PrEP for Black Canadians
Description: Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
Study NCT01489189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prompt Panretinal Photocoagulation
Description: Panretinal photocoagulation alone at baseline (full session completed within 56 days).
Study NCT01489189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5-mg Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
Study NCT01489189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deferred panretinal photocoagulation
Description: PRP is deferred until failure/futility criteria for intravitreal injection are met.
Study NCT01373762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Videogame Bikes
Description: The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
Study NCT01373762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Videogame Bikes
Description: The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
Study NCT05403099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: immediate placement of dental implant after topical application of hyaluronic acid on implant surface
Study NCT05403099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant placement
Description: immediate placement of dental implant without application of hyaluronic acid on implant surface
Study NCT03403322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kinesio taping
Description: An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.
Study NCT03403322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Without taping
Description: Children performed functional activities without tape
Study NCT01011465 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intranasal oxytocin
Description: The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
Study NCT01011465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal oxytocin
Description: The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
Study NCT01011465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
Study NCT01011465 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
Study NCT01011465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
Study NCT04909580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision coaching with a patient decision aid
Description: Decision coaching guided by the Ottawa Decision Support Framework
Study NCT00404495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
Study NCT00404495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles
Study NCT04108000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT-Dementia
Description: The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates enhanced consent techniques, such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care.
Study NCT04108000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
Study NCT04152265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy
Study NCT04152265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Description: complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
Study NCT04152265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: demographic data collections
Description: completing the demographic questionnaire
Study NCT04152265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: anthropometric data collections
Description: For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
Study NCT04152265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collecte the biological samples
Description: blood and faeces collections
Study NCT01292070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal Human Fcγ1-Fel d1 fusion protein
Description: Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.
Study NCT01292070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Positive Control - standardized cat hair allergenic extract (CAT)
Description: 4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
Study NCT01292070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Positive Control - Histamine Prick
Description: 1.0 mg/mL
Study NCT01292070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Negative Control - Intradermal Diluent
Description: Saline, Albumin with Phenol (HSA) sterile diluent
Study NCT02519101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous noninvasive blood pressure monitoring ClearSight-Device
Description: Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
Study NCT04997707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Abbott
Description: in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
Study NCT04997707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalation Solution
Description: in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
Study NCT04997707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: transcranial motor evoked potential(Tcm
Description: using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
Study NCT04858919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D transabdominal ultrasound
Description: Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
Study NCT04858919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: transrectal ultrasound
Description: The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
Study NCT04858919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vaginoscopy
Description: It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
Study NCT01330810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
Study NCT04599387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Exercise Prescription
Description: Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
Study NCT04599387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
Study NCT04092959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
Study NCT04487067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion q3w
Study NCT04487067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV Q3W
Study NCT03584620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
Study NCT03584620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band
Study NCT02007005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abnobaVISCUM Fraxini
Description: intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
Study NCT02969525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02969525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosage regimens.